GlobeNewswire: Vericel Corporation Contains the last 10 of 211 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:43:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/29/2837891/0/en/Vericel-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Full-Year-2024-Financial-Guidance.html?f=22&fvtc=4&fvtv=24786Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance2024-02-29T12:55:00Z<![CDATA[Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40%]]>https://www.globenewswire.com/news-release/2024/02/27/2836025/0/en/Vericel-to-Present-at-the-TD-Cowen-44th-Annual-Health-Care-Conference-on-Tuesday-March-5-2024.html?f=22&fvtc=4&fvtv=24786Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 20242024-02-27T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024.]]>https://www.globenewswire.com/news-release/2024/02/15/2829953/0/en/Vericel-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-29-2024.html?f=22&fvtc=4&fvtv=24786Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 20242024-02-15T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.]]>https://www.globenewswire.com/news-release/2024/02/05/2823516/0/en/Vericel-to-Present-at-the-Canaccord-Genuity-Musculoskeletal-Conference-on-Monday-February-12-2024.html?f=22&fvtc=4&fvtv=24786Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 20242024-02-05T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 11:00 a.m. ET (8:00 a.m. PT) on Monday, February 12, 2024.]]>https://www.globenewswire.com/news-release/2024/01/09/2806201/0/en/Vericel-Announces-Preliminary-Full-Year-and-Fourth-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=24786Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results2024-01-09T12:55:00Z<![CDATA[Full-Year Total Revenue Expected to be Approximately $197.5 Million, Representing 20% Growth, with Fourth Quarter Revenue Growth of 23% to $65 Million]]>https://www.globenewswire.com/news-release/2024/01/03/2803325/0/en/Vericel-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference-on-Wednesday-January-10-2024.html?f=22&fvtc=4&fvtv=24786Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 20242024-01-03T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to begin at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 10, 2024.]]>https://www.globenewswire.com/news-release/2023/11/08/2776142/0/en/Vericel-Reports-Third-Quarter-2023-Financial-Results-and-Raises-Full-Year-2023-Financial-Guidance.html?f=22&fvtc=4&fvtv=24786Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance2023-11-08T12:55:00Z<![CDATA[Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year]]>https://www.globenewswire.com/news-release/2023/11/07/2775110/0/en/Vericel-to-Present-at-the-Stephens-Annual-Investment-Conference.html?f=22&fvtc=4&fvtv=24786Vericel to Present at the Stephens Annual Investment Conference2023-11-07T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will present at the Stephens Annual Investment Conference. The fireside chat will begin at 10:00 a.m. ET (9:00 a.m. CT) on Wednesday, November 15, 2023.]]>https://www.globenewswire.com/news-release/2023/10/25/2766522/0/en/Vericel-to-Report-Third-Quarter-2023-Financial-Results-on-November-8-2023.html?f=22&fvtc=4&fvtv=24786Vericel to Report Third-Quarter 2023 Financial Results on November 8, 20232023-10-25T12:30:00Z<![CDATA[CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.]]>https://www.globenewswire.com/news-release/2023/09/28/2751212/0/en/Vericel-Announces-Publication-of-Positive-Results-from-Phase-3-Debride-and-Protect-DETECT-Study-of-Thermal-Burn-Patients-Treated-with-NexoBrid.html?f=22&fvtc=4&fvtv=24786Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid2023-09-28T12:30:00Z<![CDATA[Data published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared to Gel Vehicle and standard of care]]>